<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016263</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068616</org_study_id>
    <secondary_id>GENTA-GM301</secondary_id>
    <secondary_id>UCLA-0207109</secondary_id>
    <nct_id>NCT00016263</nct_id>
  </id_info>
  <brief_title>Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma</brief_title>
  <official_title>Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Oblimersen (G3139) may help dacarbazine kill more cancer cells by&#xD;
      making tumor cells more sensitive to the drug. It is not yet known if dacarbazine is more&#xD;
      effective with or without oblimersen (G3139).&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or&#xD;
      without oblimersen (G3139) in treating patients who have advanced malignant melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the survival of patients with advanced malignant melanoma treated with&#xD;
           dacarbazine with or without oblimersen (G3139).&#xD;
&#xD;
        -  Compare the response rate, durable response rate, and progression-free survival of&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the safety of these regimens in this patient population.&#xD;
&#xD;
        -  Compare the performance status, body weight, and tumor-related symptoms of patients&#xD;
           treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to ECOG performance status (0 vs 1 or 2), extent of metastases and lactate&#xD;
      dehydrogenase (LDH) level (skin subcutaneous and/or lymph node metastases without visceral&#xD;
      involvement and normal LDH vs any visceral metastases or elevated LDH), and liver metastases&#xD;
      (yes vs no). Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive dacarbazine IV over 60 minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive oblimersen (G3139) IV continuously over days 1-6 followed by&#xD;
           dacarbazine IV over 60 minutes on day 6.&#xD;
&#xD;
      Treatment repeats every 21 days for a maximum of 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients with stable disease or partial or complete&#xD;
      response may be eligible for another 8 courses of treatment in an extension protocol.&#xD;
&#xD;
      Patients are followed at least every 2 months for up to 2 years after study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 750 patients (375 per arm) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant melanoma&#xD;
&#xD;
               -  Progressive disease that is unresectable or metastatic&#xD;
&#xD;
          -  No primary ocular or mucosal melanoma&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion by physical exam or imaging studies&#xD;
&#xD;
               -  At least 10 mm by caliper for superficial cutaneous disease&#xD;
&#xD;
               -  At least 20 mm by contrast-enhanced or spiral CT scan for visceral or nodal/soft&#xD;
                  tissue disease&#xD;
&#xD;
               -  No bone metastases as only site of measurable disease&#xD;
&#xD;
               -  Lesions considered non-measurable include the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging&#xD;
&#xD;
                    -  Lesions located in a previously irradiated area&#xD;
&#xD;
          -  No brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  Considered a medical candidate for dacarbazine treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (hematopoietic growth factor or transfusion independent)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT/AST no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Albumin at least 2.5 g/dL&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times ULN&#xD;
&#xD;
          -  No history of chronic hepatitis or cirrhosis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV disease&#xD;
&#xD;
          -  No symptomatic coronary artery disease (e.g., uncontrolled arrhythmias or recurrent&#xD;
             chest pain despite prophylactic medication)&#xD;
&#xD;
          -  No cardiovascular signs and symptoms at least grade 2 within the past 4 weeks&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Intellectually, emotionally, and physically able to maintain an ambulatory infusion&#xD;
             pump&#xD;
&#xD;
          -  Satisfactory venous access&#xD;
&#xD;
          -  No other significant medical disease&#xD;
&#xD;
          -  No uncontrolled seizure disorder&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No known hypersensitivity to phosphorothioate-containing oligonucleotides or&#xD;
             dacarbazine&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy, cytokine, biologic, or vaccine therapy in&#xD;
             the adjuvant and/or metastatic setting and recovered&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF], sargramostim&#xD;
             [GM-CSF] or epoetin alfa) during course 1 of study&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy, including regional perfusion&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent chronic corticosteroids with an average dose of at least 20 mg of&#xD;
             prednisone or equivalent per day&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to measurable target lesions unless progression occurred at that&#xD;
             site or measurable disease developed outside the treated area&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior surgery and recovered&#xD;
&#xD;
          -  No prior organ allografts&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior experimental therapy&#xD;
&#xD;
          -  No prior intratumoral injection therapy to measurable target lesions unless&#xD;
             progression occurred at that site or measurable disease developed outside the treated&#xD;
             area&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No concurrent anticoagulation therapy except 1 mg/day of warfarin for central line&#xD;
             prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley R. Frankel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Genta Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genta Incorporated</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

